



BioCryst to Present at Two Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- [BioCryst Pharmaceuticals, Inc.](http://www.BioCryst.com) (NASDAQ:BCRX) today announced that [executives from BioCryst](#) are scheduled to present and provide a corporate summary and update regarding the Company's clinical programs at the following investor conferences:

- 11th Annual JMP Securities Research Conference in San Francisco on Tuesday, May 15, 2012 at 11:30 a.m. Pacific Time
- Bank of America Merrill Lynch Healthcare Conference in Las Vegas on Wednesday, May 16, 2012 at 5:00 p.m. Pacific Time

Links to live audio webcasts and replays of both presentations may be accessed on the BioCryst website at www.BioCryst.com.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in infectious and inflammatory diseases. BioCryst currently has two late-stage development programs: [peramivir](#), a viral neuraminidase inhibitor for the treatment of influenza, and [BCX4208](#), a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of gout. In addition, BioCryst is advancing two preclinical programs towards IND filings: [BCX5191](#), a nucleoside analog inhibitor of HCV RNA polymerase (NS5B) for hepatitis C, and [BCX4161](#), an oral inhibitor of plasma kallikrein for hereditary angioedema. Utilizing state-of-the-art structure-guided drug design and crystallography, BioCryst continues to discover innovative compounds with the goal of addressing unmet medical needs of patients and physicians. For more information, please visit the Company's website at www.BioCryst.com.

This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at <http://investor.shareholder.com/biocryst/sec.cfm>.

BCRXW

BioCryst Pharmaceuticals
Robert Bennett, +1-919-859-7910

Source: BioCryst Pharmaceuticals

News Provided by Acquire Media